trending Market Intelligence /marketintelligence/en/news-insights/trending/3mosftm5iaa2smrwkkjziq2 content esgSubNav
In This List

Sanofi gets EU nod, US priority tag for rare blood clotting disorder drug

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


Sanofi gets EU nod, US priority tag for rare blood clotting disorder drug

Sanofi said the European Commission approved its drug Cablivi for treating acquired thrombotic thrombocytopenic purpura, or aTTP, a rare blood clotting disorder.

The disease causes extensive clots in a patient's small blood vessels, causing low platelet count, loss of red blood cells, restricted blood supply and organ damage. Cablivi was developed by Ablynx NV — a company Sanofi acquired in January.

The marketing authorization is based on a phase 3 study called Hercules and a phase 2 study called Titan. The EU regulator's nod follows a recommendation by the European Medicines Agency in June to approve the therapy.

Sanofi Genzyme, the Paris-based company's specialty care business unit, will work with authorities to make Cablivi available to patients across Europe.

Meanwhile, the U.S. Food and Drug Administration also granted priority review to Cablivi for treating patients 18 years and older experiencing an episode of aTTP. The U.S. regulator is expected to make a decision by Feb. 6, 2019.